Vice President of Chemistry- Marek Cholody, PhD
Vice President of Chemistry - Marek Cholody, PhD
has been involved in drug discovery for over 20 years.
Upon completion of his PhD in Medicinal Chemistry at the Technical University of Gdansk, Poland, he joined the faculty of the Department of Pharmaceutical Technology and Biochemistry where he conducted research focused on the design and synthesis of small molecule anticancer agents.
This led to the discovery of a new class of drugs - the imidazoacridones.
The leading compound in this class, C-1311, is presently in Phase 2 clinical trials under the name Symadex.
In 1993, Dr. Cholody joined the Molecular Aspects of Drug Design team at the National Cancer Institute, where he discovered and developed two new classes of potential anticancer and anti-AIDS agents.
In 2001, he joined Avalon Pharmaceuticals as a Research Group Leader in the Medicinal Chemistry Department where he was instrumental in establishing and validating Avalon's gene expression-based drug discovery platform.
His work at Avalon led to AVN316 which was nominated as clinical candidate in company's beta-catenin program.
Dr. Cholody is an expert in DNA-interacting anticancer agents.
has published 26 papers and has 9 issued patents on anticancer drugs.